Revelation Biosciences (REVB) Expected to Post Earnings on Friday

Revelation Biosciences (NASDAQ:REVB) is expected to announce its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect Revelation Biosciences to post earnings of ($0.83) per share for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Revelation Biosciences (NASDAQ:REVB) last issued its earnings results on Thursday, May 7th. The company reported ($2.71) EPS for the quarter, missing the consensus estimate of ($1.15) by ($1.56). On average, analysts expect Revelation Biosciences to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Revelation Biosciences Trading Up 1.8%

Shares of Revelation Biosciences stock opened at $1.15 on Thursday. The stock has a 50-day moving average price of $1.04 and a 200 day moving average price of $1.29. The company has a market cap of $4.49 million, a P/E ratio of -0.03 and a beta of -0.15. Revelation Biosciences has a 1 year low of $0.88 and a 1 year high of $11.72.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Revelation Biosciences presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Revelation Biosciences stock. Armistice Capital LLC grew its position in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) by 442.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 434,272 shares of the company’s stock after buying an additional 354,272 shares during the quarter. Armistice Capital LLC owned approximately 6.29% of Revelation Biosciences worth $347,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.80% of the stock is owned by institutional investors.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.